Antonia Rotolo
Antonia Rotolo
Email verificata su
Citata da
Citata da
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
A Chaidos, V Caputo, K Gouvedenou, B Liu, I Marigo, MS Chaudhry, ...
Blood, The Journal of the American Society of Hematology 123 (5), 697-705, 2014
Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen …
E Messa, S Carturan, C Maffè, M Pautasso, E Bracco, A Roetto, F Messa, ...
Haematologica 95 (8), 1308, 2010
Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting
A Rotolo, VS Caputo, M Holubova, N Baxan, O Dubois, MS Chaudhry, ...
Cancer Cell 34 (4), 596-610. e11, 2018
The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma
A Rotolo, V Caputo, A Karadimitris
British Journal of Haematology 173 (3), 350-364, 2016
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
NJ Mason, N Chester, A Xiong, A Rotolo, Y Wu, S Yoshimoto, P Glassman, ...
MAbs 13 (1), 2004638, 2021
Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies
A Rotolo, A Karadimitris, M Ruella
Leukemia & lymphoma 59 (9), 2040-2055, 2018
CRISPR-Cas9 knock out of CD5 enhances the anti-tumor activity of chimeric antigen receptor T cells
I Chun, KH Kim, YH Chiang, W Xie, YGG Lee, R Pajarillo, A Rotolo, ...
Blood 136, 51-52, 2020
Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer
A Rotolo, MJ Atherton, BT Kasper, KP Haran, NJ Mason
STAR protocols 2 (4), 100905, 2021
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
K Watanabe, AM Gomez, S Kuramitsu, M Siurala, T Da, S Agarwal, ...
Blood advances 7 (14), 3416-3430, 2023
Case report: clinical and serological hallmarks of cytokine release syndrome in a canine B cell lymphoma patient treated with autologous CAR-T cells
MJ Atherton, A Rotolo, KP Haran, NJ Mason
Frontiers in Veterinary Science 9, 824982, 2022
The next questions in chronic myeloid leukaemia and their answers
D Marin, A Rotolo, D Milojkovic, J Goldman
Current opinion in hematology 20 (2), 163-168, 2013
Emerging drugs for chronic myeloid leukemia
D Cilloni, E Messa, A Rotolo, G Saglio
Expert Opinion on Emerging Drugs 15 (2), 175-184, 2010
Systemic Mastocytosis: An Intriguing Disorder
A Rotolo, U Familiari, P Nicoli, D Cilloni, G Saglio, A Guerrasio
Hematology - Science and Practice 18, 467-486, 2012
Abstract# 2866: EphA3 is abnormally expressed in chronic myeloprolipherative disorders and could represent a new molecular target
F Arruga, F Messa, S Carturan, M Pradotto, C Maffè, M Pautasso, ...
Cancer Research 69 (9_Supplement), 2866-2866, 2009
Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients
A Rotolo, EC Whelan, MJ Atherton, I Kulikovskaya, D Jarocha, JA Fraietta, ...
Cell Reports Medicine 4 (10), 2023
Detection of humoral immune responses against WT1 antigen in patients affected by different hematological malignancies
P Nicoli, I Defilippi, S Carturan, A Roetto, F Messa, F Arruga, E Messa, ...
Acta Haematologica 120 (1), 47-50, 2008
Disabled gene is involved in CML progression and its expression level at diagnosis can predict major molecular response (MMR) to imatinib therapy
F Arruga, F Messa, M Pradotto, R Bernardoni, E Bracco, S Carturan, ...
Cancer Research 70 (8_Supplement), 251-251, 2010
Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression.
D Cilloni, M Pradotto, F Messa, F Arruga, E Bracco, S Carturan, C Maffè, ...
Blood 114 (22), 3470, 2009
Herpetic leg paralysis and abdominal ileus in a patient with idiopathic myelofibrosis
P Nicoli, M Bosa, A Rotolo, D Cilloni, G Saglio
Internal and emergency medicine 4, 65-66, 2009
Fratricide-resistant anti-CD2 chimeric antigen receptor T-cells with endogenous CD2 knockout are highly effective against T-cell neoplasms
MG Angelos, RP Patel, YH Chiang, W Xie, R Pajarillo, CE Shaw, E Singh, ...
Blood 142, 885, 2023
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20